Tilray’s Mixed Quarter: Record Revenue Amid Persistent Losses

Tilray Brands has unveiled its first-quarter 2025 financial results, revealing a complex picture of robust revenue growth coupled with ongoing financial challenges. The cannabis giant reported record sales of $200 million, marking a 13 percent increase compared to the same period last year. However, these impressive top-line figures mask underlying difficulties that continue to plague the company’s bottom line.

Beverage Division Emerges as Powerhouse

While cannabis remains the company’s traditional core business, the beverage alcohol segment demonstrated explosive growth, surging 132 percent to reach $56 million in revenue. This performance has positioned Tilray among the top five craft beer producers in the United States. The company’s diversified business segments showed varying performance levels:

• Beverage alcohol: $56.0 million (+132%) with 41% margin
• Cannabis: $61.2 million with 40% margin
• Distribution: $68.1 million with 12% margin
• Wellness: $14.8 million (+11%) with 32% margin

Profitability Metrics Show Strength, But Losses Persist

The company’s profitability indicators presented a bright spot in the quarterly report. Gross profit jumped 35 percent to $59.7 million, while the gross margin expanded to 30 percent from 25 percent—a notable 500-basis-point improvement that highlights enhanced operational efficiency.

Despite these gains and record revenue, Tilray remained deeply unprofitable on a net basis. The company posted a net loss of $34.7 million, though this represented a 38 percent improvement year-over-year. On a per-share basis, the adjusted loss narrowed to $0.01.

Should investors sell immediately? Or is it worth buying Tilray?

Cash Flow Concerns and European Prospects

A significant area of concern emerged in the company’s cash flow statement. Free cash flow deteriorated to negative $42.0 million—more than twice as deep as the previous year’s negative figure. Adjusted EBITDA stood at $9.3 million, while cash reserves totaled $205.2 million.

Internationally, the German market is showing promising developments following cannabis legalization. Revenue from medical cannabis in Germany jumped 50 percent. CEO Irwin Simon has pointed to increasing discussion of cannabis policy from both U.S. presidential candidates as potentially creating additional momentum for further liberalization measures.

Strategic Expansion and Fundamental Questions

Through its Tilray Alternative Beverages division, the company is now pushing into the U.S. market for hemp-based Delta-9 THC drinks. This strategic initiative aims to leverage the company’s expertise in cannabis compounds within mainstream beverage markets.

The fundamental question facing investors remains unchanged: when will aggressive growth translate into sustainable profitability? While Tilray’s diversified approach across cannabis, beverages, wellness products, and distribution provides some insulation against market volatility, the persistent negative cash flow indicates the path to consistent profitability remains challenging.